Syncope and Collapse

🩺What is Syncope and Collapse?

The San Francisco Syncope Rule (SFSR) was developed by Dr. Quinn and colleagues at the University of California, San Francisco, and published in Annals of Emergency Medicine in 2004. The rule was derived from a cohort of 791 patients presenting to the ED with syncope or near-syncope. It identifies patients at risk for serious 30-day outcomes including death, myocardial infarction, arrhythmia, pulmonary embolism, stroke, subarachnoid hemorrhage, significant hemorrhage, or recurrent syncope leading to hospitalization. The original rule used 5 criteria (abnormal ECG, dyspnea, hematocrit <30%, systolic BP <90, history of CHF), while subsequent validation studies expanded to include age >65 as a sixth criterion. When any single criterion is present, the sensitivity for detecting serious outcomes is approximately 96-98%, with a specificity of about 56-62%. A negative SFSR (no criteria present) confers a <1% risk of serious 30-day outcome, making it a useful rule-out tool. The SFSR is endorsed by the American College of Emergency Physicians (ACEP) clinical policy for syncope.

📊Clinical Assessment & Risk Scoring

Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Syncope and Collapse:

• San Francisco Syncope Rule

  The San Francisco Syncope Rule (SFSR) is a clinical decision rule that identifies patients with syncope at high risk for serious 30-day outcomes. It uses 6 clinical predictors to stratify risk in the emergency department setting.

🧬Diagnostic Logic & Scoring Breakdown

The SFSR is positive if any one of the six clinical predictors is present. Each predictor is scored as 0 (absent) or 1 (present). A total score ≥1 indicates high risk for a serious 30-day outcome (approximately 11% incidence). A score of 0 (no predictors present) indicates low risk (approximately 0.6% incidence). Age >65 years recognizes that advanced age independently increases the probability of cardiac and non-cardiac serious outcomes. Systolic BP <90 mmHg at triage identifies hemodynamic instability. History of congestive heart failure suggests underlying structural heart disease. Abnormal ECG includes any new changes (ischemia, arrhythmia, pacemaker malfunction) or non-sinus rhythm. Hematocrit <30% (or hemoglobin <10 g/dL) identifies significant anemia that may have precipitated syncope. Dyspnea (shortness of breath) preceding or accompanying syncope may suggest pulmonary embolism or cardiac ischemia.

📢Clinical Significance & Implications

Syncope accounts for 1-3% of all ED visits and up to 6% of hospital admissions. The SFSR helps clinicians identify which syncope patients require hospital admission versus those who can be safely discharged. A negative SFSR (no criteria met) has a negative predictive value of >99% for serious 30-day outcomes. The SFSR has been validated in multiple international ED populations with consistent sensitivity of 89-98%, though specificity varies (41-63%). It is one of the most widely studied syncope clinical decision rules and is incorporated in the ACEP clinical policy for syncope management. Key limitations include its lower specificity leading to potentially unnecessary admissions, and reduced accuracy in patients with syncope mimics (seizure, hypoglycemia, stroke). The rule is best applied to patients with syncope as the primary presenting complaint, not as an incidental finding. The CHESS study also identified that patients with a negative SFSR plus a normal BNP and normal troponin have an even lower risk, suggesting combined strategies may improve specificity.

💡 Clinical Assessment Scenario Example

A 72-year-old woman presents to the ED after a witnessed syncopal episode at a grocery store. She reports feeling short of breath before passing out. Vital signs: BP 88/56 mmHg, HR 88. ECG shows atrial fibrillation (new onset). Hct: 28%. She has a history of CHF (ejection fraction 40%). SFSR: Age >65 (yes, +1), SBP <90 (yes, +1), CHF history (yes, +1), Abnormal ECG (yes, +1), Hct <30% (yes, +1), Dyspnea (yes, +1). Score: 6/6 — SFSR positive, high risk for serious 30-day outcome. Admitted for telemetry, echocardiogram, and further management.

🔗Related Diseases & Conditions

These conditions are clinically associated with Syncope and Collapse through shared risk-scoring calculators and assessment tools:

• Congestive Heart Failure

⚠️Clinical Assessment Pitfalls

• ❌ Mistake: Applying SFSR to patients with syncope mimics (seizure, hypoglycemia, stroke, head trauma)

  ✅ Correction: SFSR is validated only for patients with syncope or near-syncope as the primary presentation. Do not use for seizure, hypoglycemia, or other altered mental status causes.

• ❌ Mistake: Interpreting any abnormal ECG finding as SFSR-positive

  ✅ Correction: Only new ECG changes, non-sinus rhythm, or pacemaker malfunction count. Chronic stable abnormalities without change should not be counted.

• ❌ Mistake: Using SFSR to rule out non-syncope causes of collapse

  ✅ Correction: SFSR predicts serious outcomes in syncope patients. It does not diagnose the cause of syncope and does not replace clinical judgment for specific etiologies like PE or MI.

🚑When to Seek Medical Attention

This reference supports clinical assessment of Syncope and Collapse; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.

❓Frequently Asked Questions

📚Evidence-Based References